Heart failure treatment adherence and quality of life;Adhesión al tratamiento y calidad de vida en los pacientes con insuficiencia cardiaca

Revista Espanola de Cardiologia Suplementos

Volumn 7, Issue F, 2007, Pages

  Conthe, Pedro ^a   Tejerina, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Heart failure; Quality of life; Treatment adherence

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; SPIRONOLACTONE;

CLINICAL EVALUATION; HEALTH CARE COST; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTERVIEW; MEDICAL DECISION MAKING; MEDICAL SOCIETY; PATIENT CARE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

EID: 38149098480     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(07)75256-1     Document Type: Article

References (62)

1. WHO Adherence to Long Term Therapies Project II. Global Adherence Interdisciplinary Network. Geneve: World Health Organization; 2003.
2. Rodríguez-Artalejo F, Banegas Banegas JR, Guallar-Castellón P. Epidemilogía de la insuficiencia cardiaca. Rev Esp Cardiol. 2004;57:163-70.
3. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC. The epidemiology of heart failure. Eur Heart J. 1997;18:208-23.
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-9.
5. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-9.
6. Sorensen TI. The changing lifestyle in the world. Body weight and what else? Diabetes Care. 2002;23:1-4B.
7. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-90.
8. McInnes GT. Integrated approaches to management of hypertension, promoting treatment acceptance. Am Heart J. 1999;138:25S-5.
9. Christensen DB, Williams B, Golbers HI, Martin DP, Engelberg R, Logerfo JP. Assesing compliance to hypertensive medications using computed-based pharmacy records. Med Care. 1997;35:1252-62.
10. Caro JJ, Salas M, Raggio G, Jackson JD. Effects of the initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160:41-6.
11. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counselling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization, a randomized, controlled trial. Pharmacotherapy. 2000;20:410-6.
12. Kavanagh DJ, Gooley S, Wilson PH. Prediction of adherence and control in diabetes. J Behav Med. 1993;6:509-22.
13. Somons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid lowering drugs. Med J Austr. 1996;164:208-1.
14. Márquez Contreras E, Casado Martínez JJ. El incumplimiento farmacológico en las enfermedades cardiovasculares. Med Clin (Barc). 2001;116 Supl 2:46-51.
15. Rotter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance, a metaanalysis. Med Care. 1998;36:1138-61.
16. Gans KM, Lapane KL, Lasater TM, Carleton RA. Effect of intervention on compliance to referral and lifestyle recommendations given at cholesterol screening programs. Am J Prev Med. 1994;10:275-82.
17. Raynor DK, Booth TG, Blenkinsopp A. Effects of computer generated reminder charts on patients compliance with drug regimens. BMJ. 1993;306:1158-61.
18. Osterberg L, Blaschke T. Adherence to medication. N Eng J Med. 2005;353:487-97.
19. Cegala DJ, Marinelli T, Post D. The effects of patient comunication skills training on compliance. Arch Farm Med. 2000;9:57-64.
20. Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, et al. CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366:2005-11.
21. Remme WJ, Swedberg K. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-60.
22. Conthe P, Visus E. La importancia del cumplimiento terapéutico en la insuficiencia cardiaca. Med Clin (Barc). 2005;124:302-7.
23. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Eng J Med. 2002;347:1397-402.
24. Rizzo JA, Simmons WR. Variations in compliance among hypertensive patients with drug class: implications of health care costs. Clin Ther. 1996;19:1446-57.
25. Puigventos Latorre F, Llodrá Ortolá V, Vilanove Boltó M, Delgado Sánchez O, Lázaro Ferreruela M, Forteza- Rey Borralerás J, et al. Cumplimiento terapéutico en el tratamiento de la hipertensión: 10 años de publicaciones en España. Med Clin (Barc). 1997;109:702-6.
26. Márquez Contreras E, Casado Martínez JJ, Ramos Gómez J, Saenz Soubrier S, Moreno García JP, Celotti Gómez B, et al. Influencia del cumplimiento terapéutico en los niveles de presión arterial en el tratamiento de la hipertensión arterial. Hipertensión. 1998;15:133-9.
27. Márquez Contreras E, Casado Martínez JJ, Martínez Vázquez M, Moreno García JP, Fernández Ortega A, et al. Análisis de la influencia del cumplimiento terapéutico en las presiones arteriales, y grado de control de la HTA mediante monitorizació n ambulatoria de la presión arterial. Med Clin (Barc). 2001;116 Supl 2:114-21.
28. Márquez Contreras E, Casado Martínez JJ, López de Andrés M, Corés Prieto E, López Zamorano JM, Moreno García JP, et al. Cumplimiento terapéutico en las dislipemias. Ensayo sobre la eficacia de la educación sanitaria. Aten Primaria. 1998;22:79-84.
29. Gil VF, Belda J, Piñeiro F, Merino J. Métodos para medir el cumplimiento terapéutico En: Gil VF, Belda J, Piñeiro F, Merino J, editores. El cumplimiento terapéutico. Madrid: Doyma; 1999. p 77-90.
30. Mc Kenney JM, Munroe WP, Wright JT. Impact on electronic medication compliance aid on long-term pressure control. J Clin Pharmacol. 1992;32:277-83.
31. Márquez E, Casado JJ, Márquez JJ. Estrategias para mejorar el cumplimiento terapéutico. FMC. 2001;8:558-73.
32. Grupo de Trabajo IC de la SEMI. La IC en los servicios de medicina interna de España. Registro SEMI-IC. Med Clin (Barc). 2002;118:605-10.
33. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmand AM, Francis GS, et al. American College of Cardiology/American Heart Association. Guidelines for the evaluation and management of chronic heart failure in adults. Circulation. 2001;104:2296-3007.
34. Heart Failure: evaluation and care of patients with left ventricular disfunction. Maryland: US Department of Health and Human Services. Publication no. 4-0612; 1994.
35. Anguita M, Ojeda S, Atienza F, Ridocci F, Almenar L. Análisis de coste beneficio de los programas de prevención de reingresos en pacientes hospitalizados por insuficiencia cardiaca. Impacto económico de las nuevas formas de asistencia a la insuficiencia cardiaca. Rev Esp Cardiol. 2005;58 Supl 2:32-6.
36. Morcillo C, Valderas JM, Aguado O, Delás J, Sort D, Pujadas R, et al. Evaluación de una intervención domiciliaria en pacientes con insuficiencia cardiaca. Resultados de un estudio aleatorizado. Rev Esp Cardiol. 2005;58:618-25.
37. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen Solal A, Aguilar C, and Study Group on diagnosis in the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe (I): patients characteristics and diagnosis. Eur Heart J. 2003;24:442-63.
38. Chui MA, Deer M, Bennett SJ, Tu W, Oury S, Brater DC, et al. Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy. 2003;23:326-32.
39. González B, Lupón J, Parajón T, Urrutia A, Altimir S, Coll R, et al. Nurse evaluation of patients in a new multidisciplinary Heart Failure Unit in Spain. Eur J Cardiovasc Nurs. 2004;3:61-9.
40. Horne R, Weinman J. Patients beliefs about prescribed medicines and their role in adherence to treatment in chronic physichal illness. J Psychosom Res. 1999;47:555-67.
41. Remme WJ, McMurray J, Rauch B, Zannad F, Keukelaar K, Cohen A, for the SHAPE StudyHeart Failure Awareness and Perception in Europe: a Pan-European general public survey on awareness and perception of the clinical, social and economic importance of heart failure in the community. ESC Congress; september, 2003.
42. Grupo de Trabajo Insuficiencia Cardiaca de la SEMI. Insuficiencia cardiaca: recomendaciones diagnósticas y terapéuticas de la Sociedad Española de Medicina Interna. Madrid. Jarpyo; 2006.
43. Cleland JG, Gemmel I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur Heart Fail. 1999;1:229-41.
44. Mayor S. NICE issues new guidelines for patients with heart failure. BMJ. 2003;327:179.
45. Casado JM, Visus E, Recio JP, Sánchez Ledesma M, Chimeno M, Roca B, et al. Neurohormonal blockade in patients with heart failure at discharge from hospital. An Med Interna. 2006;23:478-82.
46. Román-Sánchez P, Conthe P, García Alegría J, Forteza-Rey J, Montero M, Montoto C. Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey. Q J Med. 2005;98:127-38.
47. Bohachick P, Burke LE, Sereika S, Murali S, Dunbar-Jacob J. Adherence to angiotensin converting enzyme inhibitor therapy for heart failure. Prog Cardiovasc Nurs. 2002;17:160-6.
48. Struthers AD, Anderson G, McFadyen RJ, Fraser C, McDonald TM. Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays. Heart. 1999;82:584-8.
49. Struthers AD, McFadyen RJ, Fraser C, Robson J, Morton JJ, Junot C, et al. Non-adherence with angiotensin converting enzyme inhibitor therapy. A comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol. 1999;34:2072-7.
50. Ni H, Nauman D, Burguess D, Wise K, Hershberger RE. Factors influencing knowledge of and adherence to self- care among patients with heart failure. Arch Intern Med. 1999;159:1613-9.
51. Murberg TA, Bru E, Svebak S, Tveteras R, Aarsland T. Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure, a two year follow up study. Int J Psychiatry Med. 1999;29:311-32.
52. Hoobs R. Can heart failure be diagnosed en primary care? BMJ. 2000;321:188-9.
53. Bloom BS. Continuation of initial antihypertensive medication after 1 year therapy. Clin Ther. 1998;20:671-81.
54. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al. Studies of Left Ventricular Dysfunction Investigators. Baseline quality of life as a predictor of mortality and hospitalization in 5025 patients with congestive heart failure: SOLVD investigations. Am J Cardiol. 1996;78:890-5.
55. Faller H, Steinbuchel T, Schowalter M, Spertus JA, Stork S, Angermann CE. The Kansas City Cardiomiopathy Questionnaire (KCCQ): a new disease-specific quality of life measure for patients with chronic heart failure. Psychoter Psychosom Med Psychol. 2005;55:200-8.
56. Stull DE, Clough LA, Van Dussen D. Self report quality of life as a predictor of hospitalization for patients with LV dysfunction: a life course approach. Res Nurs Health. 2001;24:460-9.
57. Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J, et al. Prediction of outcome by neurohormonal activation, the six minute walk test and The Minnessota Living With Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J. 2002;23:886-91.
58. Alonso Prieto L, Antó JM. La versión española del SF-36 Health Survey (cuestionario de salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc). 1995;104:771-6.
59. Rector TS, Kubo SH, Cohn JN. Patient's self assesesment of their congestive heart failure, part 2: content, reliability and validity of a new measure, the Minnessota Living With Heart Failure Questionnaire. Heart Fail. 1987;3:198-209.
60. Parajón T, Lupón J, González B, Urrutia A, Altimir S, Coll R, et al. Use of The Minnessota Living With Heart Failure Quality of Life Questionnaire in Spain. Rev Esp Cardiol. 2004;57:155-60.
61. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016-24.
62. Rodríguez Artalejo F, Guallar-Castillón P, Rodríguez Pascual C, Otero CM, Montes AO, García AN, et al. Health. Related Quality of life as a predictor of hospital readmission and death among patients with Herat failure. Arch Intern Med. 2005;165:1274-9.